MDLN vs WST
Medline Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
MDLN
Medline Inc.
51
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | MDLN | WST |
|---|
| AI Score |
51
|
74
|
| Price |
$35.02
|
$351.74
|
| P/E Ratio |
40.74×
|
44.65×
|
| ROE |
10.8%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
25.0%
|
36.8%
|
| Debt / Equity |
1.09×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
37.7
|
58.0
|
| Beta |
-0.4106
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MDLN versus WST.
WST leads by 23 points.
WST scores 74/100 (Buy) versus MDLN at 51/100 (Watch).
MDLN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 64.1 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 64.1 is expensive by classic value standards — Value
- Price-to-book of 5.0x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical